Fludarabine Dose Intensity, Lymphodepletion Biology, and Product-Specific Outcomes in Large B-Cell Lymphoma CAR-T Therapy: Interpreting the 2026 EBMT Registry Analysis

Fludarabine Dose Intensity, Lymphodepletion Biology, and Product-Specific Outcomes in Large B-Cell Lymphoma CAR-T Therapy: Interpreting the 2026 EBMT Registry Analysis

A large EBMT registry study suggests that escalating fludarabine during lymphodepletion does not improve tisagenlecleucel outcomes in LBCL and may worsen survival, while axicabtagene ciloleucel retains superior efficacy at standard dosing but with more neurotoxicity.
Cesarean Scar Pregnancy Continued Beyond the First Trimester Carries High Risks of Pregnancy Loss, Placenta Accreta Spectrum, and Hysterectomy

Cesarean Scar Pregnancy Continued Beyond the First Trimester Carries High Risks of Pregnancy Loss, Placenta Accreta Spectrum, and Hysterectomy

International registry data show that expectant management of live cesarean scar ectopic pregnancy is frequently followed by second-trimester loss, placenta accreta spectrum, and peripartum hysterectomy, with first-trimester ultrasound markers helping identify women at highest risk.